RU2658911C2 - Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека - Google Patents

Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека Download PDF

Info

Publication number
RU2658911C2
RU2658911C2 RU2014145544A RU2014145544A RU2658911C2 RU 2658911 C2 RU2658911 C2 RU 2658911C2 RU 2014145544 A RU2014145544 A RU 2014145544A RU 2014145544 A RU2014145544 A RU 2014145544A RU 2658911 C2 RU2658911 C2 RU 2658911C2
Authority
RU
Russia
Prior art keywords
degrees
polymorph
cancer
compound
methyl
Prior art date
Application number
RU2014145544A
Other languages
English (en)
Russian (ru)
Other versions
RU2014145544A (ru
Inventor
Кевин Уэйн КУНТЦ
Куань-чунь ХУАН
Хиеонг Воок Чои
Кристен САНДЕРС
Стивен МАТЬЕ
Арани ЧАНДА
Фрэнк ФАН
Original Assignee
Эпизайм, Инк.
ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО. ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизайм, Инк., ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО. ЛТД. filed Critical Эпизайм, Инк.
Publication of RU2014145544A publication Critical patent/RU2014145544A/ru
Application granted granted Critical
Publication of RU2658911C2 publication Critical patent/RU2658911C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
RU2014145544A 2012-04-13 2013-04-11 Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека RU2658911C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624215P 2012-04-13 2012-04-13
US61/624,215 2012-04-13
PCT/US2013/036193 WO2013155317A1 (en) 2012-04-13 2013-04-11 Salt form of a human hi stone methyltransf erase ezh2 inhibitor

Publications (2)

Publication Number Publication Date
RU2014145544A RU2014145544A (ru) 2016-06-10
RU2658911C2 true RU2658911C2 (ru) 2018-06-26

Family

ID=49328166

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014145544A RU2658911C2 (ru) 2012-04-13 2013-04-11 Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека

Country Status (26)

Country Link
US (7) US9394283B2 (OSRAM)
EP (4) EP4190777A1 (OSRAM)
JP (3) JP6255382B2 (OSRAM)
KR (4) KR102438340B1 (OSRAM)
CN (2) CN108358899B (OSRAM)
AU (2) AU2013245878B2 (OSRAM)
BR (1) BR112014025508B1 (OSRAM)
CA (1) CA2870005C (OSRAM)
CY (2) CY1119383T1 (OSRAM)
DK (3) DK3628670T3 (OSRAM)
ES (3) ES2745016T3 (OSRAM)
HR (2) HRP20170295T1 (OSRAM)
HU (3) HUE060881T2 (OSRAM)
IL (4) IL282732B2 (OSRAM)
IN (1) IN2014DN09068A (OSRAM)
LT (2) LT3184523T (OSRAM)
MX (2) MX384641B (OSRAM)
NZ (1) NZ700761A (OSRAM)
PL (3) PL2836491T3 (OSRAM)
PT (3) PT2836491T (OSRAM)
RS (2) RS55690B1 (OSRAM)
RU (1) RU2658911C2 (OSRAM)
SG (3) SG10201608577RA (OSRAM)
SI (2) SI3184523T1 (OSRAM)
SM (2) SMT201700132T1 (OSRAM)
WO (1) WO2013155317A1 (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
SG11201406440TA (en) 2012-04-13 2014-11-27 Epizyme Inc Combination therapy for treating cancer
DK3628670T3 (da) 2012-04-13 2022-12-05 Epizyme Inc Saltform til ezh2-hæmning
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
NZ706739A (en) * 2012-10-15 2018-11-30 Epizyme Inc Substituted benzene compounds
EP2908823B1 (en) 2012-10-15 2019-09-25 Epizyme, Inc. Methods of treating cancer
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2910873A1 (en) 2013-04-30 2014-11-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
AU2014288839B2 (en) 2013-07-10 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
CN105829302B (zh) 2013-10-16 2020-09-08 Epizyme股份有限公司 用于ezh2抑制的盐酸盐形式
WO2015058125A1 (en) * 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
WO2015077193A1 (en) * 2013-11-19 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
EP3888659A1 (en) 2013-12-06 2021-10-06 Epizyme Inc Combination therapy for treating cancer
SG11201610273VA (en) 2014-06-17 2017-01-27 Epizyme Inc Ezh2 inhibitors for treating lymphoma
ES2725928T3 (es) 2014-06-20 2019-09-30 Constellation Pharmaceuticals Inc Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida
IL310279A (en) 2014-10-16 2024-03-01 Epizyme Inc Method for treating cancer
PL3220916T3 (pl) * 2014-11-17 2023-08-14 Epizyme, Inc. Sposób leczenia raka n-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5-(etylo(tetrahydro-2h-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'-bifenylo]-3-karboksyamidem
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2016172199A1 (en) 2015-04-20 2016-10-27 Epizyme, Inc. Combination therapy for treating cancer
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
EA201890567A1 (ru) 2015-08-24 2018-08-31 Эпизайм, Инк. Способ лечения рака
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2017218953A1 (en) 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
WO2018137639A1 (zh) * 2017-01-25 2018-08-02 恩瑞生物医药科技（上海）有限公司 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
EP3678663A4 (en) 2017-09-05 2021-06-02 Epizyme, Inc. POLYTHERAPY FOR CANCER TREATMENT
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
SI4003532T1 (sl) 2019-07-24 2025-02-28 Constellation Pharmaceuticals, Inc. Kristalinične oblike 7-kloro-2-(4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-N-((6-metil-4-(metilthio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamida
KR20220066892A (ko) 2019-08-22 2022-05-24 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
CN115175904A (zh) * 2019-12-20 2022-10-11 Epizyme股份有限公司 Ezh2抑制剂的结晶氢溴酸盐、其制备和用于治疗癌症的药物组合物
WO2022208552A1 (en) * 2021-03-31 2022-10-06 Msn Laboratories Private Limited, R&D Center Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004122114A (ru) * 2002-02-18 2005-05-27 Астразенека Аб (Se) Химические соединения
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
HUT74450A (en) 1993-12-27 1996-12-30 Eisai Co Ltd Anthranilic acid derivative and pharmaceutical compns. contg. such compds.
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
EP1117635A1 (en) 1998-09-30 2001-07-25 The Procter & Gamble Company 2-substituted ketoamides
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
EP1357111B1 (en) 2000-12-28 2009-08-05 Shionogi & Co., Ltd. 2-pyridone derivatives having affinity for cannabinoid type 2 receptor
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
DE60329981D1 (de) 2002-02-19 2009-12-24 Shionogi & Co Antipruriginosa
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
MXPA06010520A (es) 2004-03-30 2007-03-26 Chiron Corp Derivados de tiofeno sustituidos como agentes anticancerosos.
EP1765994B1 (en) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7923219B2 (en) 2005-06-02 2011-04-12 The University Of North Carolina At Chapel Hill Ubiquitin E3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP2388258A1 (de) 2005-10-19 2011-11-23 Grünenthal GmbH Neue Vanilloidrezeptor-Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
CN101291910A (zh) 2005-10-21 2008-10-22 默克公司 钾通道抑制剂
WO2007053480A2 (en) 2005-10-28 2007-05-10 The University Of North Carolina At Chapel Hill Protein demethylases comprising a jmjc domain
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP5167149B2 (ja) 2006-01-20 2013-03-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 白血病の診断および治療ターゲット
RU2008149246A (ru) 2006-05-15 2010-06-20 Айрм Ллк (Bm) Соединение на основе терефталата, композиции и их применение в качестве ингибиторов интегразы вич
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
CA2666461A1 (en) 2006-10-10 2008-09-12 Burnham Institute For Medical Research Neuroprotective compositions and methods
JP2010519204A (ja) 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US8299093B2 (en) 2008-08-08 2012-10-30 New York Blood Center, Inc. Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
JP2012522013A (ja) 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション 調節ｉｒｅｓ媒介翻訳
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US8329149B2 (en) 2009-12-30 2012-12-11 Avon Products, Inc. Topical lightening composition and uses thereof
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
PH12012502194A1 (en) * 2010-05-07 2014-09-05 Glaxosmithkline Llc Indoles
JP6389036B2 (ja) 2010-09-10 2018-09-12 エピザイム インコーポレイテッド ヒトｅｚｈ２の阻害剤、およびその使用方法
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012075080A1 (en) 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
WO2012075500A2 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
HUE042271T2 (hu) 2012-03-12 2019-06-28 Epizyme Inc Emberi EZH2 inhibitorai és azok alkalmazási eljárásai
DK3628670T3 (da) 2012-04-13 2022-12-05 Epizyme Inc Saltform til ezh2-hæmning
SG11201406440TA (en) 2012-04-13 2014-11-27 Epizyme Inc Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
EP2908823B1 (en) 2012-10-15 2019-09-25 Epizyme, Inc. Methods of treating cancer
CN105829302B (zh) 2013-10-16 2020-09-08 Epizyme股份有限公司 用于ezh2抑制的盐酸盐形式

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004122114A (ru) * 2002-02-18 2005-05-27 Астразенека Аб (Se) Химические соединения
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles

Also Published As

Publication number Publication date
PT2836491T (pt) 2017-02-08
LT3184523T (lt) 2020-02-10
US9394283B2 (en) 2016-07-19
CY1122883T1 (el) 2022-03-24
JP2018199740A (ja) 2018-12-20
KR102120883B1 (ko) 2020-06-09
SG11201406468YA (en) 2015-01-29
MX2014012380A (es) 2015-07-23
IL296199A (en) 2022-11-01
US12251386B2 (en) 2025-03-18
US10245269B2 (en) 2019-04-02
HUE031976T2 (en) 2017-08-28
EP3628670B1 (en) 2022-10-12
JP6255382B2 (ja) 2017-12-27
US11491163B2 (en) 2022-11-08
SG10201608577RA (en) 2016-12-29
IL296199B1 (en) 2024-08-01
SMT201900501T1 (it) 2019-11-13
AU2018200168A1 (en) 2018-02-01
US20180243316A1 (en) 2018-08-30
RS55690B1 (sr) 2017-07-31
CN104603130B (zh) 2018-04-27
AU2018200168B2 (en) 2019-08-29
SI2836491T1 (sl) 2017-06-30
EP3184523A1 (en) 2017-06-28
PL3628670T3 (pl) 2023-02-20
IL282732B2 (en) 2023-04-01
KR20220123339A (ko) 2022-09-06
US9872862B2 (en) 2018-01-23
SMT201700132T1 (it) 2017-05-08
KR102744039B1 (ko) 2024-12-17
IL296199B2 (en) 2024-12-01
PT3184523T (pt) 2019-09-26
US20170143729A1 (en) 2017-05-25
EP4190777A1 (en) 2023-06-07
HUE060881T2 (hu) 2023-04-28
LT2836491T (lt) 2017-03-27
KR20250005505A (ko) 2025-01-09
DK3184523T3 (da) 2019-08-19
AU2013245878A1 (en) 2014-10-30
IL235045B (en) 2019-05-30
SI3184523T1 (sl) 2020-04-30
RU2014145544A (ru) 2016-06-10
JP2018002742A (ja) 2018-01-11
ES2617379T3 (es) 2017-06-16
EP2836491B1 (en) 2016-12-07
US20190269692A1 (en) 2019-09-05
PL3184523T3 (pl) 2019-12-31
IL282732A (en) 2021-06-30
IN2014DN09068A (OSRAM) 2015-05-22
HUE045353T2 (hu) 2019-12-30
WO2013155317A1 (en) 2013-10-17
EP2836491A1 (en) 2015-02-18
IL266165A (en) 2019-06-30
US20250268905A1 (en) 2025-08-28
NZ700761A (en) 2016-09-30
IL282732B (en) 2022-12-01
MX362339B (es) 2019-01-11
DK2836491T3 (en) 2017-03-06
IL235045A0 (en) 2014-12-31
US20230140327A1 (en) 2023-05-04
KR20200066380A (ko) 2020-06-09
KR102438340B1 (ko) 2022-08-30
KR20150002730A (ko) 2015-01-07
EP3628670A1 (en) 2020-04-01
BR112014025508B1 (pt) 2020-11-17
CA2870005A1 (en) 2013-10-17
PL2836491T3 (pl) 2017-08-31
CN104603130A (zh) 2015-05-06
JP2015512942A (ja) 2015-04-30
PT3628670T (pt) 2022-12-02
US10821113B2 (en) 2020-11-03
RS59392B1 (sr) 2019-11-29
ES2745016T3 (es) 2020-02-27
CN108358899B (zh) 2021-07-27
SG10201912109QA (en) 2020-02-27
HRP20170295T1 (hr) 2017-04-21
HRP20191653T1 (hr) 2020-02-21
EP2836491A4 (en) 2015-09-16
IL266165B (en) 2021-06-30
CA2870005C (en) 2021-06-22
ES2931316T3 (es) 2022-12-28
JP6634058B2 (ja) 2020-01-22
DK3628670T3 (da) 2022-12-05
CY1119383T1 (el) 2018-02-14
CN108358899A (zh) 2018-08-03
MX384641B (es) 2025-03-14
AU2013245878B2 (en) 2017-10-12
EP3184523B1 (en) 2019-06-19
US20150065503A1 (en) 2015-03-05
US20210137936A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
RU2658911C2 (ru) Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека
HK40087682A (en) Hbr salt form for ezh2 inhibition
HK40026825B (en) Salt form for ezh2 inhibition
HK40026825A (en) Salt form for ezh2 inhibition

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170922

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20171017